

CytoJournal

www.cytojournal.com



Executive Editor

Vinod B. Shidham, MD, FIAC, FRCPath
WSU School of Medicine & Detroit Medical Center, Detroit, MI, USA

Editors-in-Chief

Lester J. Layfield, MD
University of Missouri, Columbia, MO USA
Vinod B. Shidham, MD, FIAC, FRCPath
WSU School of Medicine & Detroit Medical Center, Detroit, MI, USA

Open Access
in
cytopathology



Empowering
authors
&
readers

PubMed



Cytopathology Foundation
www.cytojournal.com



ScientificScholar[®]
Knowledge is power

Publisher of Scientific Journals



Editorial

Revisiting open-access versus non-open-access conventional publications in cytopathology

Andre Kajdacsy-Balla, MD, PhD¹ Vinod B. Shidham, MD, FRCPath, FIAC²

¹Department of Pathology, University of Illinois School of Medicine, Chicago, Illinois, ²Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, United States.



*Corresponding author:

Andre Kajdacsy-Balla, MD, PhD,
Department of Pathology,
University of Illinois School of
Medicine, Chicago, Illinois.

aballa@uic.edu

Received : 21 August 2021

Accepted : 21 August 2021

Published : 30 August 2021

DOI

10.25259/Cytojournal_37_2021

Quick Response Code:



Recently published study published in this journal demonstrated that open-access (OA) cytopathology journals accrued a higher citation rate as compared to the conventional non-OA cytopathology journals irrespective of their free access status.^[1]

In OA, authors retain their copyright in the public domain without losing their intellectual property to any of their work in that publication. This allows unique flexibility for researchers and original authors to use their work for future review articles, chapters, and books using figures and tables (as it is or after some modifications if needed) by just citing the original OA publication source. The same is applicable if any OA publication is required in part or full for teaching and academic non-commercial purpose.^[2-4]

Citation per article for both types of non-OA cytopathology journal articles irrespective of their free access status was lower than OA category.^[1] The study highlighted that the authors prefer OA platform, irrespective of their free availability status. Some non-OA journals allow the articles to be available as free resource but usually after some post-publication gap. This may lead the scholar not to prefer such articles. Increasing number of scholars is realizing the advantages and long-term impact without losing the hard earned copyright to their creation.

The Creative Commons Copyright License (CCCL) provides tools to manage balanced application of the traditional “all rights reserved” mindset because of usual copyright laws. CCCL extends tools for both individual scholars and large entities including publishers, printers, and academic institutions.^[5] This simplifies the process in a standardized fashion by granting copyright permissions to the creative works. This has impacted OA publication with creation of ever expanding platforms such as Digital Commons,^[6] which is a pool of OA content which may be copied, distributed, edited, remixed, and built upon. All these are possible due to CCCL within the boundaries of copyright laws.^[5]

In addition to many benefits related to the internet, special benefits of the OA articles include easy, quick real-time access, and referral to various cross references in the articles reviewed by the researchers, if the articles were in OA [Table 1]. In contrast, non-OA articles had to be purchased or find a source subscribing to these journals with disruption in the review process compromising the ability to review the scientific literature in seamless fashion. Many review articles in OA^[7-9] could use previously published sketches and figures with benefit of referring to those original articles if needed as additional resources. Internet-based advantages allow inclusion of videos.^[10,11] It also allows provision for automatic translations in various languages in the world, real-time consultation with researchers and comments/rebuttal, etc. The above benefits

Table 1: Summary of some of benefits with OA articles.

#	Benefits of OA
1	Increased impact of the publication for individual authors.
2	Easy quick seamless access to the scientific literature in real time.
3	Because of the copyright sharing principle of OA under CCCL, figures and sketches along with other data could be used seamlessly with or without modification in many review articles and OA chapters. ^[7-9]
4	Overall cost to the general public and authors is significantly reduced with exponentially high output.
5	Very important emergence of unique publication platform for rapid advances in science.
6	Many benefits of internet could be applied including inclusion of videos, ^[10,11] provision for automatic translations in various languages in the world, real-time consultation with researchers and comments/rebuttal.

OA: Open access, CCCL: Creative Commons Copyright License

at large are popularizing the OA publications with obvious reasons for its emergence and widespread preference.

These benefits are increasingly appreciated by intelligentsia and scholars with increasing attempts to prefer OA option. However, the OA model for self-advancement with financial independence requires special approach. The commonly used model is raising revenue through Article Publication Cost (APC) which range from \$1350 to \$ 5700.^[12,13] Such cost may be acceptable to the scholars publishing grant-based research, which allows payment for APC through grant funding. However, most authors publish non-grant-based research or other scholarly work and for them there may not be funding for paying APC.

To balance this dilemma, CytoJournal as scientific journal publishing diagnostic and clinical cytopathology literature has designed a unique model. In this model, the non-profit organization, Cytopathology Foundation Inc. (CF) which supports CytoJournal's OA platform, accepts membership at low cost. All CF members get multiple benefits^[14] which include total waiver of APC for all articles accepted after peer review and published in CytoJournal during their membership in good standing. Unfortunately, even professional organizations fail to protect the copyrights of the work of their members in addition to significantly high membership cost.

With CytoJournal, all cytopathology authors have access to OA platform in cytopathology at very nominal cost with many benefits.^[14] This concept is extended further with provision to publish scholarly work as books at low cost through CytoJournal Monograph/Atlas Series project by Cytopathology Foundation^[8,9,15,16] in collaboration with Scientific Scholar.^[17]

In summary, OA publishing extends many benefits related to the internet in addition to special benefits such as convenience of quick real-time access and referral to various cross-references without disruption in the review process during the review of the scientific literature seamlessly online [Table 1]. For example, many review articles in OA^[7-9] could use previously published sketches and figures in review articles and chapters after citing the original source.

LIST OF ABBREVIATIONS (IN ALPHABETIC ORDER)

APC: Article Publication Cost
 CCCL: Creative Commons Copyright License
 CF: Cytopathology Foundation
 CPA: Citations per Article
 Dwlds: Downloads
 IP: Intellectual property
 JASC: Journal of American Cytopathology
 J of Cytology: Journal of Cytology
 non-OA: Non-open access
 OA: Open access

REFERENCES

1. Kolpekwar JA, Shidham VB. Impact of cytopathology authors work: Comparative analysis based on open-access cytopathology publications versus non-open-access conventional publications. *Cytojournal* 2021;18:20.
2. Frisch NK, Nathan R, Ahmed YK, Shidham VB. Authors attain comparable or slightly higher rates of citation publishing in an open access journal (CytoJournal) compared to traditional cytopathology journals a five year (2007-2011) experience. *Cytojournal* 2014;11:10.
3. Shidham VB, Demay RM. Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013). *Cytojournal* 2013;10:18.
4. Shidham VB, Pitman MB, Demay RM, Atkinson BF. CytoJournal's move to the new platform: More on financial model to the support open-access charter in cytopathology, publication quality indicators, and other issues. *Cytojournal* 2008;5:15.
5. The Creative Commons Copyright License. Available from: <https://www.creativecommons.org/about/cclicenses>. [Last accessed on 2021 Jul 24].
6. Digital Commons: bepress. Available from: <https://www.bepress.com/products/digital-commons>. [Last accessed on 2021 Jul 20].
7. CMAS books (CytoJournal). Available from: <https://www.cytojournal.com/monographs>. [Last accessed on 2021 Jul 20].
8. Shidham VB. (CMAS #1) E-Book Version; 2021. Available from: <https://www.cytojournal.com/monograph-series-1>. [Last accessed on 2021 Aug 26].
9. Shidham VB. *CellBlockistry* 101. 1st ed. Michigan, US: CytoJournal Monograph (CMAS), Cytopathology Foundation Inc.; 2021.

10. Joshi M, Scarff G. Rare infection diagnosed by cytology in a bronchoalveolar lavage specimen in a patient with massive pulmonary hemorrhage. *Cytojournal* 2020;17:23.
11. Shidham VB. Updates in processing of anterior fat pad aspirate for amyloid (with video and sketches). *Cytojournal* 2020;17:15.
12. Publication Fees by Journals; 2021. Available from: https://www.openwetware.org/wiki/Publication_fees. [Last accessed on 2021 Jul 24].
13. Callaos N. Costs, Prices, and Revenues in Journals Publishing, The International Institute of Informatics and Systemics: IIIS; 2011. Available from: <http://www.iiisci.org/journal/sci/Costs.pdf> [Last accessed on 2021 Aug 28].
14. CF Membership. Available from: <https://www.cytojournal.com/cf-member> [Last accessed on 2021 Aug 28].
15. Langham-Putrow A, Bakker C, Riegelman A. Is the open access citation advantage real? A systematic review of the citation of open access and subscription-based articles. *PLoS One* 2021;16:e0253129.
16. Shidham VB, Bose S, Baloch Z, Layfield LJ. *CytoJournal* monographs: First CMAS (*cytojournal* monograph/atlas series) on science of cell-block making, titled "cellblockistry 101 (text book of cell-blocking science)". *Cytojournal* 2021;18:10.
17. Scientific Scholar. Available from: <https://www.scientificscholar.com>. [Last accessed on 2021 Jul 24].

How to cite this article: Kajdacsy-Balla A, Shidham VB. Revisiting open-access versus non-open-access conventional publications in cytopathology. *CytoJournal* 2021;18:21.

HTML of this article is available FREE at: https://dx.doi.org/10.25259/Cytojournal_37_2021

The FIRST Open Access cytopathology journal

Publish in *Cytojournal* and **RETAIN** your *copyright* for your intellectual property

Become Cytopathology Foundation Member to get all the benefits
Annual membership fee is nominal US \$ 50 (US \$ 1000 for life)
In case of economic hardship it is free
For details visit <https://cytojournal.com/cf-member>

PubMed indexed
FREE world wide **open access**
Online processing with rapid turnaround time.
Real time dissemination of time-sensitive technology.
Publishes as many colored high-resolution images
Read it, cite it, bookmark it, use RSS feed, & many----

CYTOJOURNAL

www.cytojournal.com

Peer-reviewed academic cytopathology journal






NextGen CelBloking™ Kits

**Frustrated with your cell blocks?
We have a better solution!**

Nano

Nano NextGen CelBloking™

Cell block kit to process single scattered cell specimens and tissue fragments of **any** cellularity.



PATENT PENDING



Pack #1



Pack #2

Micro

Micro NextGen CelBloking™

For cellular specimens (more than 1 ml concentrated specimen with Tissuecrit more than 50%)



PATENT PENDING



Pack #1



Pack #2



Co-Editors-in-Chief

Lester J. Layfield, MD, University of Missouri, USA

Vinod B. Shidham, MD, FRCPath, FIAC, Wayne State University, USA

Assistant Editor

Nora Frisch, MD, The University of Vermont Medical Center, USA

CytoJ Monograph Committee Co-chairs

Zubair Baloch, MD, PhD, USA

Shikha Bose, MD, USA

CytoJ Monograph Co-editors-in-chief

R. Marshal Austin, MD, PhD, USA

Ruth Katz, MD, USA

David C. Wilbur, MD, USA

Cytotechnology Panel

Jamie L. Covell BS, CT(ASCP), USA

Inderpreet Dhillon, MS, CT (ASCP), USA

Kalyani Naik, MS, SCT(ASCP), USA

Hempath-Cytopath corner

Lead Section Editor

Ali M. Gabali, MD, PhD, USA

Section Editors

Chung-Che (Jeff) Chang, MD, PhD, FCAP, USA

Kedar V. Inamdar, MD, USA

Lauren Barrett Smith, MD, USA

Michael Gerard Baryerl, MD, USA

Quiz Case Section

Section Editor

Tamar Giorgadze, MD, PhD, USA

QC Section Members

Amarpreet Bhalla, MD, USA

Linette Mejias-Badillo, MD, USA

Associate Editors

Shikha Bose, MD

David C. Chhieng, MD, MBA, MSHI, USA

Mamatha Chivukula, MD, USA

Isam A. Eltoum, MD, MBA, USA

Rana S. Hoda, MD, FIAC, USA

Nirag Jhala, MD, MIAC, USA

Sanjay Logani, MD, MIAC, USA

Sonya Naryshkin, MD, FIAC, USA

Liron Pantanowitz, MD, USA

Husain Saleh, MD, FIAC, MBA, USA

Momin T. Siddiqui, MD, FIAC, USA

Lourdes R. Ylagan, MD, FIAC, USA

Editorial Board Members

R. Marshall Austin, MD, PhD (USA)

Zubair Baloch, MD, PhD (USA)

George Birdsong, MD (USA)

Thomas A. Bonfiglio, MD (USA)

Shikha Bose, MD (USA)

David C. Chhieng, MD, MBA, MSHI (USA)

Mamatha Chivukula, MD (USA)

Douglas P Clark, MD (USA)

Michael B. Cohen, MD (USA)

Diane D Davey, MD (USA)

Richard M DeMay, MD (USA)

Hormoz Ehya, MD (USA)

Isam A. Eltoum, MD, MBA (USA)

James England, MD, PhD (USA)

Yener S Erozan, MD (USA)

Prabodh Gupta, MBBS,MD, FIAC (USA)

Amanda Herbert, MBBS, FRCPath (UK)

Rana S. Hoda, MD (USA)

Nirag Jhala, MD, MIAC (USA)

Kusum Kapila, MD, FIAC, FRCPath (Kuwait)

Ruth Katz, MD (USA)

Savitri Krishnamurthy, MD (USA)

Leyster Layfield, MD (USA)

Santo V Nicosia, MD (USA)

Virginia LiVolsi, MD (USA)

Britt-Marie Ljung, MD (USA)

Sanjay Logani, MD, FCAP, FASCP, MIAC (USA)

Shahla Masood, MD (USA)

Dina R Mody, MD (USA)

Sonya Naryshkin, MD, FIAC (USA)

Martha B Pitman, MD ((USA)

Liron Pantanowitz, MD (USA)

David C Wilbur, MD (USA)

Husain Saleh, MD, FIAC, MBA (USA)

Torill Sauer, MD (Norway)

Volker Schneider, MD, FIAC (Germany)

Suzanne Selvaggi, MD (USA)

Momin T. Siddiqui, MD, FIAC (USA)

Vinod B Shidham, MD, FRCPath, FIAC (USA)

Mary K Sidawy, MD (USA)

Rosemary Tambouret, MD(USA)

Jan F Silverman, MD (USA)

Philippe Vielh, MD (France)

Lourdes R. Ylagan, MD, FIAC (USA)

Kusum Verma, MBBS, MD, MIAC (India)

CytoJournal Virtual Trainee (CVT) Corner

Section Editors

Lead Section Editor

Walid E. Khalbuss, MD, PhD, Saudi Arabia

Zubair Baloch, MD, PhD, USA

Guido Fadda, MD, Italy

Liron Pantanowitz, MD, USA

Paul Tranchida, MD, USA

Medicolegal Panel

Dennis R. McCoy, JD, USA

Mark S. Sidoti, Esq., USA

Michael S. Berger, JD, USA

Ken Gatter, MD, JD, USA

Statistical Advisor

Varghese George, PhD, USA

Global Health (Cytology)

Rajan Dewar, MD PhD, USA

Managing Editor

Anjani Shidham, BS, USA



International Editorial Panel

Argentina

Ricardo Drut, MD
Boris Elsner, MD
Lucrecia Illescas, MD, FIAC

Australia

Andrew Field MB BS (Hons), FRCPA, FIAC

Belgium

John-Paul Bogers, MD, PhD
Alain Verhest, MD, PhD, FIAC

Brazil

Joaõ Prolla, MD
Vinicius Duval da Silva, MD, M.I.A.C.

Canada

Manon Auger, MD, FRCP(C)
Diponkar Banerjee, MBChB, FRCPC, PhD
Terence J. Colgan, MD, FRCPC, FCAP, MIAC

China

Terence J. Colgan, MD, FRCPC, FCAP,
MIAC Dongge Liu, MD/PhD

France

Beatrix Cochand-Priollet, MD, PhD, MIAC
Jerzy Klijanienko, MD

Germany

Magnus von Knebel Doeberitz, MD, PhD
Ulrich Schenck, MD

India

Deepali Jain, MD, DNB, MNAMS, FIAC
Shubhada Kane, MD

Prakash Patil, MD, PhD

Arvind Rajwanshi, MD, MNAMS, FRCPath
Ravi Mehrotra, MD, MNAMS

Italy

Guido Fadda, MD
Pio Zeppa, MD

Japan

Toshiaki, Kawai, MD
Robert Y. Osamura, MD

Jordan

Maher A. Sughayer, MD

Lebanon

Nina Salem Shabb, MD

Netherlands

Mathilde E. Boon, MD

Norway

Torill Sauer, MD

Pakistan

Syed Mulazim Hussain Bukhari,
MBBS, DCP, FCPS, PhD

Poland

Włodzimierz T. Olszewski, MD PhD

Portugal

Margarida Almeida, MD
Evelina Mendonça, MD, MIAC
Fernando Carlos de Landér Schmitt, MD

Saudi Arabia

Mousa A. Al-Abbadi, MD, FCAP, FIAC

Singapore

Alexander Russell Chang, MD (Otago), FRCPA
Aileen Wee, MBBS, MRCPPath, FRCPA

South Africa

Pam Michelow, MBBCh, MSc (Med Sci), MIAC

Spain

Jose M. Rivera Pomar, MD
Mercedes Santamaria Martinez, MD

Sweden

Annika Dejmek, MD, PhD
Karin Lindholm, MD
Edneia Tani, MD

Turkey

Binnur Uzmez Onal, MD, FEBP, FIAC
Mehmet Akif Demir, MD

UK

John H. F. Smith, MD
Allan Wilson, MD

Uruguay

Carmen Alvarez Santin, MD

Vietnam

Nguyen Sao Trung, MD, PhD